Core Viewpoint - Wei Jun Biotechnology (00660.HK) reported a revenue of approximately HKD 377 million for the fiscal year ending June 30, 2025, representing an increase of about 1.9% compared to the previous year. The company also improved its net loss to approximately HKD 14.6 million from HKD 44.2 million in the prior year, primarily due to a significant reduction in impairment losses on non-financial assets [1]. Financial Performance - The group's revenue and gross profit remained relatively stable compared to the previous year, with a reported revenue of approximately HKD 377 million [1]. - The net loss for the fiscal year ending June 30, 2025, was approximately HKD 14.6 million, a significant improvement from the net loss of approximately HKD 44.2 million for the fiscal year ending June 30, 2024 [1]. - The improvement in net loss was mainly attributed to a substantial decrease in impairment losses on non-financial assets during the reporting period [1]. Strategic Outlook - The company plans to continue pursuing strategic acquisitions to capture new business opportunities in the Chinese market, aiming to further strengthen its revenue and profit base [1]. - The company is actively seeking projects with growth potential for acquisition or investment and is in discussions with various parties regarding such opportunities [1].
玮俊生物科技(00660.HK)年度收入约3.77亿港元 同比增加约1.9%